These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Dendritic cell-based cancer immunotherapy targeting MUC-1. Wierecky J; Mueller M; Brossart P Cancer Immunol Immunother; 2006 Jan; 55(1):63-7. PubMed ID: 15864588 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma]. Wang H; Feng F; Zhu M; Wang R; Wang X; Wu Y; Zhuang Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Jan; 31(1):67-71. PubMed ID: 25575061 [TBL] [Abstract][Full Text] [Related]
9. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. Höltl L; Rieser C; Papesh C; Ramoner R; Herold M; Klocker H; Radmayr C; Stenzl A; Bartsch G; Thurnher M J Urol; 1999 Mar; 161(3):777-82. PubMed ID: 10022683 [TBL] [Abstract][Full Text] [Related]
14. [Specific cellular immunotherapy of renal cell carcinoma. Current status and prospects]. Ringhoffer M; Gschwend JE Urologe A; 2002 May; 41(3):249-57. PubMed ID: 12132274 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for renal cell cancer. Yang JC; Childs R J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543 [TBL] [Abstract][Full Text] [Related]
16. [Immune anticancer response: recent advances in the treatment of renal cell carcinoma]. Bouet F; Catros V Ann Biol Clin (Paris); 2004; 62(3):257-68. PubMed ID: 15217758 [TBL] [Abstract][Full Text] [Related]
17. Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma. Laurell A; Lönnemark M; Brekkan E; Magnusson A; Tolf A; Wallgren AC; Andersson B; Adamson L; Kiessling R; Karlsson-Parra A J Immunother Cancer; 2017; 5():52. PubMed ID: 28642820 [TBL] [Abstract][Full Text] [Related]
18. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-alpha plus IL-2 and IL-12). Merad M; Angevin E; Wolfers J; Flament C; Lorenzi I; Triebel F; Escudier B; Zitvogel L J Immunother; 2000; 23(3):369-78. PubMed ID: 10838666 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based immunotherapy in prevention and treatment of renal cell carcinoma: efficacy, safety, and activity of Ad-GM·CAIX in immunocompetent mouse models. Birkhäuser FD; Koya RC; Neufeld C; Rampersaud EN; Lu X; Micewicz ED; Chodon T; Atefi M; Kroeger N; Chandramouli GV; Li G; Said JW; McBride WH; Kabbinavar FF; Ribas A; Pantuck AJ; Belldegrun AS; Riss J J Immunother; 2013 Feb; 36(2):102-11. PubMed ID: 23377663 [TBL] [Abstract][Full Text] [Related]
20. Translational mini-review series on vaccines: Dendritic cell-based vaccines in renal cancer. Ranieri E; Gigante M; Storkus WJ; Gesualdo L Clin Exp Immunol; 2007 Mar; 147(3):395-400. PubMed ID: 17302887 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]